´╗┐Recently, targeting EGFR and downstream effectors in PI3K/AKT/mTOR pathways has been attractive, for they are complementary targets and among the most generally aberrant molecules in malignant gliomas [3]

´╗┐Recently, targeting EGFR and downstream effectors in PI3K/AKT/mTOR pathways has been attractive, for they are complementary targets and among the most generally aberrant molecules in malignant gliomas [3]. study in depth the complex molecular biology of glioma, develop novel regimens targeting GSCs, and identify biomarkers to stratify patients with the individualized molecular targeted therapy. Here, […]